Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva unseats Pfizer

Executive Summary

Based on prescriptions dispensed, Teva has become the top pharmaceutical company in the U.S. following its merger with Ivax. Pro-forma 2005 numbers from IMS put the combined company at 364 mil. annual scripts, versus 324 mil. for previously number one Pfizer, which is starting to emphasize its fast-growing Greenstone generic business (1"The Pink Sheet" Feb. 20, 2006, p. 21). In terms of sales, Teva will be the 14th largest pharma company in the U.S. The company expects the $7.4 bil. acquisition will aid its geographic expansion and price negotiations (2"The Pink Sheet" Aug. 1, 2005, p. 19)...

You may also be interested in...

Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics

Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts